Does Life-Long Reduction in Low-Density Lipoprotein Cholesterol Reduce the Risk of New-Onset Hypertension?

American Journal of Cardiology

Volumn 98, Issue 8, 2006, Pages 1122-

  Messerli, Franz H ^a   Bangalore, Sripal ^a   Egan, Brent M ^a   Julius, Stevo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALLELE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DYSLIPIDEMIA; HUMAN; HYPERTENSION; LETTER; PREVALENCE; PRIORITY JOURNAL;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; CHOLESTEROL, LDL; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; TETRAZOLES;

EID: 33749253679     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.06.004     Document Type: Letter

References (5)

1. Cohen J.C., Boerwinkle E., Mosley T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354 (2006) 1264-1272
2. Jones D.W., Chambless L.E., Folsom A.R., Heiss G., Hutchison R.G., Sharrett A.R., Szklo M., and Taylor H.A. Risk factors for coronary heart disease in African Americans: the Atherosclerosis Risk in Communities Study, 1987-1997. Arch Intern Med 162 (2002) 2565-2571
3. Halperin R.O., Sesso H.D., Ma J., Buring J.E., Stampfer M.J., and Gaziano J.M. Dyslipidemia and the risk of incident hypertension in men. Hypertension 47 (2006) 45-50
4. Robinson S.C., and Brucer M. Range of normal blood pressure: a statistical and clinical study of 11,383 persons. Arch Int Med 64 (1939) 409-444
5. Julius S., Nesbitt S., Egan B.M., Weber M.A., Michelson E.L., Kaciroti N., Black H.R., Grimm Jr. H.R., Messerli F.H., Oparil S., et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354 (2006) 1685-1697